Investment Research Report: Anuh Pharma Limited (ANUHPHR)

Analysis Date: 16 October 2026 | Current Price: ₹82.60 | Verdict: POSSIBLE Multibagger

1. Executive Summary & Catalyst Evaluation

On October 16, 2026, Anuh Pharma signed an Asset Transfer Agreement to acquire the manufacturing facility of Vanquest Pharma Pvt Ltd in Tarapur, Maharashtra, for an all-cash consideration of ₹72.90 crore. This asset acquisition delivers: - Capacity Expansion: 525 MTPA addition of API and intermediate production (+35% over its current 1,500 MTPA base to 2,025 MTPA). - Capital Commitment: ₹72.90 crore cash funded via a newly sanctioned board debt facility of up to ₹75 crore (approved October 13, 2026). - Strategic Value: Rapid inorganic addition of operational land, buildings, and plant & machinery in a key chemical zone (Tarapur), avoiding 2-3 year greenfield lead times.

While the market knew of the ₹75 Cr capex authorization three days prior, the definitive acquisition terms and asset specifics confirm genuine expansion execution.

2. Ramp-Aware Catalyst Financial Model

API manufacturing assets cannot be monetised overnight due to site transfers, trial batches, and regulatory filings.

• Base Metrics (FY26 Context):
• FY26 Revenue: ~₹776 Cr (~₹0.52 Cr per MT across current product basket)
• FY26 PAT: ~₹41.0 Cr (PAT margin: ~5.3-5.5%; EBITDA margin: ~10%)
• Trailing EPS: ~₹4.10 | Estimated Share Count: ~10.04 Cr shares | Market Cap: ~₹830 Cr

• Current ROCE: 16.0% | Pre-deal Debt: ₹0 Cr | Post-deal Debt: ~₹73 Cr (D/E: 0.21x)

• Ramp Schedule:

• Year 1 (FY27): Asset handover, validation batches, internal plant integration. Modest throughput (~100-150 MTPA). Incremental revenue: ~₹45-50 Cr (+6% uplift). Increased depreciation (~₹5 Cr) and interest (~₹6.5 Cr at ~9%) largely offset operating profit.
• Steady State (FY29 / 24-36 Months): Facility achieves 80% utilization (~420 MTPA of commercial run-rate). At current average realisations, incremental annual revenue is ~₹215-220 Cr (+28% uplift over FY26).
• Incremental Steady-State PAT: ₹215 Cr × 6.5% net margin = ~₹14.0 Cr. Adding organic growth of base business (~8% CAGR), FY29 net profit can reach ~₹65-70 Cr (EPS of ~₹6.50-7.00 vs ₹4.10 currently, an uplift of ~55-70% in aggregate earnings).

3. Industry Dynamics & Capital Intensity

• Capital Intensity: Medium. Fixed assets turn around 2.5x to 3.0x revenue at steady state.
• Execution Difficulty: Medium-High. While physical equipment is in place, pharmaceutical API facilities must clear GMP, customer audits, and export country certifications before high-value export batches are invoiced. 55% of Anuh's sales target export markets.
• Industry Structural Growth: The Indian bulk drugs industry is expanding at an 8-10% CAGR, supported by global supply chain diversification and government production incentives. However, pricing power remains low in commoditised macrolides (Erythromycin, Azithromycin).

4. Quality & Governance Check

• Balance Sheet Health: Zero debt entering the deal; adding ₹73 Cr debt against ₹352 Cr net worth is prudent and safe.
• Capital Efficiency: ROCE stands at 16.0%, passing our fundamental quality gate.
• Promoter Alignment: Promoter stake is high and consistent at 71.8% with zero pledges reported.
• Governance Integrity: Clean arm's length transaction with an unrelated entity. No dilutive equity issuance.

5. Calibrated Scenario Analysis (24-36 Months)

• Bull Assumptions: Rapid regulatory qualification of the 525 MTPA facility; product mix shifts toward higher-margin non-macrolide APIs; operating margins expand toward 12%; partial re-rating toward peer median (36x).
• Base Assumptions: Orderly 2-year ramp-up to 80% utilization; steady-state PAT margin stabilizes at 6.5%; P/E holds around 20x.
• Bear Assumptions: Price deflation in key bulk APIs; integration delays; interest and fixed depreciation drag net margins below 5%.

6. Multibagger Verdict Rationale

Anuh Pharma is graded B with a verdict of POSSIBLE (Score: 52/100). The company possesses strong balance sheet hygiene, high promoter backing, and a sharp entry valuation (~19x P/E). However, API commoditisation and the multi-step regulatory ramp of newly acquired assets moderate the immediate re-rating trajectory, making this a probable double rather than a high-certainty multi-fold compounder in the near term.

Anuh Pharma Ltd (ANUHPHR) - Equity Research Analysis (As of October 13, 2026) ## 1. Catalyst & Ramp-Aware Financial Impact Math The Board approved availing a loan of up to ₹75 Cr for purchasing manufacturing assets to expand capacity. Assuming this represents the core debt portion of an estimated ₹80-90 Cr total capex outlay: - Deal vs Scale: ₹75 Cr represents ~21.3% of net worth (₹352 Cr) and ~9.7% of FY26 revenue (~₹772 Cr). - Asset Turnover & Revenue Ramp: In bulk drugs/APIs, asset turns typically range between 1.6x and 2.2x for synthetic chemical routes. At an average turn of ~1.9x, an asset base addition of ₹80 Cr can generate ~₹150 Cr in incremental steady-state revenue. - Execution Horizon: Gestation for asset purchase, civil integration, validation batches, and obtaining client audit clearances is realistically 2 to 3 years (24-36 months). - Ramp Profile: Year 1 (FY27/early FY28) revenue uplift will be negligible (<2-3%) during civil/validation phases. Full steady-state uplift (~₹150 Cr on a ~₹775 Cr base, or ~19.5%) is projected only by FY29. - Earnings Impact: Operating margin on incremental revenues is expected around 10.0% (operating profit ~₹15 Cr). Deducting incremental depreciation (~₹5.5 Cr at 7% on assets) and interest on the ₹75 Cr borrowing (~₹6.5 Cr at 8.7%), pre-tax profit uplift in Year 1-2 is depressed. At steady-state (debt amortising), PAT uplift is estimated at ~₹8.5-9.0 Cr against FY26 PAT of ₹41.05 Cr (~21% EPS uplift). ## 2. Industry Context & Capital Intensity - Industry: Indian Bulk Drugs / APIs (specialised in macrolides like Erythromycin, Azithromycin, Roxithromycin). - Capital Intensity: Medium to High. Expansion requires clean rooms, effluent management, and strict regulatory compliance. - Expected Industry CAGR: 8.0% - 9.0%. Bulk drug demand is steady, but pricing is commoditised and exposed to Chinese competition. ## 3. Fundamental Quality (Minervini SEPA Lens) - Growth & Acceleration: FY26 revenues rose 16.6% to ₹771.6 Cr, but PAT declined 13.3% to ₹41.05 Cr due to EBITDA margin compression (down to 8.56% from 10.64%). While Q1 FY27 showed a rebound in PAT (+37.6% YoY to ₹11.42 Cr), revenue growth slowed to 3.9% YoY. Lack of consistent revenue and earnings co-acceleration. - Balance Sheet & Returns: Clean balance sheet with zero debt historically; net worth of ₹352 Cr. ROCE is moderate at 16.0%. Taking on ₹75 Cr of debt is manageable (D/E will rise to ~0.21x). - Promoter Holding: Excellent at 71.8% and unchanged across consecutive quarters. - Grade: 'C' (lacks sustained pricing power, margin expansion, and top-tier secular growth). ## 4. Calibrated Valuation & Scenarios Peer median P/E is 35.2x, whereas Anuh Pharma trades at ~18-20x trailing earnings (at ₹81.3, market cap is ~₹816 Cr based on ~10.04 Cr shares, against FY26 PAT of ₹41.05 Cr). The valuation discount reflects its commoditised product focus. - Base Case (35% upside over 30 months): Capex ramps up successfully by FY29; revenue reaches ~₹925 Cr with PAT expanding to ~₹55 Cr. P/E remains around 20x. Target Price: ~₹110. - Bull Case (95% upside): Higher-margin regulated market approvals materialize quickly, EBITDA margins expand to 12.5%, PAT hits ₹75 Cr, and market re-rates stock to 24x P/E. Target Price: ~₹179. - Bear Case (-35% downside): Margin pressure from price cuts in Erythromycin salts, delayed commercialization, and added interest/depreciation dragging PAT down to ~₹32 Cr. At 16x P/E, Target Price: ~₹51. ## 5. Verdict Rationale While the capacity expansion is a constructive step funded conservatively off a debt-free base, Anuh Pharma remains a commoditised bulk drug supplier with single-digit net margins and moderate ROCE. A 20% capacity increase over 2-3 years does not meet the criteria for a rapid compounding multibagger profile.